Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products
The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world.
Johnson & Johnson (NYSE: JNJ) today announced that following the approval of its pending acquisition of Intra-Cellular Therapies, Inc. by Intra-Cellular Therapies’ shareholders on March 27, 2025, Johnson & Johnson intends to complete its acquisition of Intra-Cellular Therapies on or around April 2, 2025.
Johnson & Johnson Inc. (NYSE: JNJ) shares are trading lower Tuesday after a U.S. bankruptcy court in Texas rejected subsidiary Red River Talc's request to approve its prepackaged bankruptcy plan.
Following the worst quarterly performance for U.S. stocks in over two years, caution dominated Wall Street as investors awaited details on the tariff plans expected from the Trump administration on Wednesday.
Shares of multinational healthcare company Johnson & Johnson (NYSE:JNJ)
fell 5.6% in the morning session after a judge in Texas rejected the company's third attempt to use bankruptcy as a legal shield against lawsuits alleging its talcum powder products caused ovarian cancer.
Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Tuesday. Stay informed about the latest market trends.
The brief revival in U.S. factory activity vanished in March as input prices shot up at the fastest pace since mid-2022, raising red flags about eroding profit margins, cost pass-through risks and strained supply chains as the U.S.
In a resounding victory for thousands of women who have suffered from ovarian cancer linked to Johnson & Johnson’s (NYSE:JNJ) talcum powder products, U.S. Bankruptcy Court Judge Christopher Lopez has rejected the company’s third attempt to shield itself from liability through bankruptcy.
Today, the U.S. Bankruptcy Court for the Southern District of Texas denied the request by Johnson & Johnson (NYSE: JNJ) (the “Company”) subsidiary Red River Talc LLC (“Red River”) to confirm its proposed prepackaged bankruptcy plan—notwithstanding that it offered one of the largest settlements ever proposed in a mass tort bankruptcy and was supported by the overwhelming majority of claimants.
Value stocks are outperforming flashy growth rivals due to market uncertainty, making value-based ETFs a good bet for steady income and diversification.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 11.1%. This drop was worse than the S&P 500’s 4% decline.
Ukraine is recognized as a country with significant mineral wealth, including a variety of rare earth elements (REEs) and other critical minerals. These resources have drawn global attention, particularly amid the ongoing war with Russia, rising geopolitical tensions, and the push for secure supply chains outside of China, which dominates
